Anti-stroke prophylaxis - The ethics of collateral damage

Journal of Clinical Neuroscience

Volumn 19, Issue 6, 2012, Pages 792-794

  Teddy, Peter ^a   Nair, Girish ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Anti stroke prophylaxis; Dabigatran; Risk in surgical emergency

Indexed keywords

ACETYLSALICYLIC ACID; DABIGATRAN ETEXILATE; ENOXAPARIN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING DISORDER; BRAIN HEMATOMA; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CRANIOTOMY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; DRUG WITHDRAWAL; EMERGENCY SURGERY; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; PROTHROMBIN TIME; REVIEW; STROKE; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

EID: 84861187401     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2012.01.024     Document Type: Article

References (17)

1. I. Melnikova The anticoagulants market Nat Rev Drug Discov 8 2009 353 354
2. Boehringer Ingelheim Pharmaceuticals IRC. Pradaxa 2011:1-5. Available from: < http://www.racgp.org.au/cmi/bycprada.pdf >.
3. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
4. H.-C. Diener, S.J. Connolly, and M.D. Ezekowitz Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial Lancet Neurol 9 2010 1157 1163
5. J.W. Eikelboom, L. Wallentin, and S.J. Connolly Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial Circulation 123 2011 2363 2372
6. J.G.T. Augoustides Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor J Cardiothorac Vasc Anesth 25 2011 1208 1212
7. S. Schulman, C. Kearon, and A.K. Kakkar Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med 361 2009 2342 2352
8. B.I. Eriksson, O.E. Dahl, and L. Ahnfelt Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I J Thromb Haemost 2 2004 1573 1580 (Pubitemid 40186173)
9. B.I. Eriksson, O.E. Dahl, and N. Rosencher Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial Lancet 370 2007 949 956 [Erratum in: Lancet 2007;370:2004] (Pubitemid 47393577)
10. B.I. Eriksson, O.E. Dahl, and N. Rosencher Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial J Thromb Haemost 5 2007 2178 2185 (Pubitemid 47617868)
11. G.J. Hankey, and J.W. Eikelboom Dabigatran etexilate: a new oral thrombin inhibitor Circulation 123 2011 1436 1450
12. M. Watanabe, F.M. Siddiqui, and A.I. Qureshi Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment Neurocrit Care 16 2011 203 209
13. J. Stangier, K. Rathgen, and H. Stähle Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study Clin Pharmacokinet 49 2010 259 268
14. J. Stangier, K. Rathgen, and H. Stähle The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects Br J Clin Pharmacol 64 2007 292 303 (Pubitemid 47283865)
15. J. van Ryn, J. Stangier, and S. Haertter Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 103 2010 1116 1127
16. W. Zhou, S. Schwarting, and S. Illanes Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran Stroke 42 2011 3594 3599
17. M. Ganetsky, K.M. Babu, and S.D. Salhanick Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant J Med Toxicol 7 2011 281 287